natgillin/translations-raw huggingface dataset:
breathing problems, asthma or chronic obstructive pulmonary disease poor blood circulation disease (such as Raynaud’s disease or Raynaud’s syndrome)
težave z dihanjem, astmo ali kronično obstrukcijsko pljučno bolezen. bolezen z motnjami krvnega obtoka (kot je Raynaudova bolezen ali Raynaudov sindrom).
breathing problems, asthma or chronic obstructive pulmonary disease poor blood circulation disease (such as Raynaud’s disease or Raynaud’s syndrome)
težave z dihanjem, astmo ali kronično obstruktivno pljučno bolezen; bolezen z motnjami v prekrvavitvi (kot je Raynaudova bolezen ali Raynaudov sindrom);
breathing problems, cough, dry throat, difficulty in swallowing,
težave z dihanjem, kašelj, suho žrelo, težave s požiranjem,
Breathing problems: Kadcyla can cause serious breathing problems such as shortness of breath (either at rest or while performing any type of activity) and cough.
Težave z dihanjem: Zdravilo Kadcyla lahko povzroči resne težave z dihanjem, na primer kratko sapo (lahko v mirovanju ali med izvajanjem kakršne koli dejavnosti) in kašelj.
breathing trouble chest pain
težave z dihanjem bolečina v prsnem košu
breathlessness
težave z dihanjem (zasoplost)
breathlessness
zadihanost
Breathlessness
zasoplost
breathlessness
zasoplost;
Breathlessness (dyspnoea)
zadihanost (dispneja)
breathlessness (including breathlessness at night)
težave z dihanjem (vključno s težavami z dihanjem ponoči),
breathlessness (including breathlessness at night),
težave z dihanjem (vključno s težavami z dihanjem ponoči),
Breathlessness and other symptomatic outcomes:
Zadihanost in drugi simptomski izidi:
Breathlessness, difficulty breathing when lying down, swelling of the feet or legs (signs of heart failure)
zadihanost, oteženo dihanje v ležečem položaju, otekanje stopal ali nog (znaki srčnega popuščanja)
breathlessness, hiccups, nasal congestion, sore throat
zasoplost, kolcanje, nazalna kongestija, boleče grlo
breathlessness.
zasoplost.
Breathlessness:
Težko dihanje:
Breathlessness:
Zadihanost:
Brecon Road, Hay-on-Wye, Hereford HR3 5PG
Hereford HR3 5PG
Breelib nebuliser
Nebulator Breelib
Brentford, Middlesex TW8 9GS United Kingdom
Brentford, Middlesex TW8 9GS Velika Britanija
Brentford, Middlesex TW8 9GS United Kingdom
Brentford, Middlesex, TW8 9GS Velika Britanija
Bretaris Genuair 322 mcg inhalation powder Aclidinium (aclidinium bromide)
Bretaris Genuair 322 mikrogramov/odmerek prašek za inhaliranje aklidinij (aklidinijev bromid)
Bretaris Genuair contains lactose monohydrate
Zdravilo Bretaris Genuair vsebuje laktozo monohidrat
Bretaris Genuair is a medicine that contains the active substance aclidinium bromide.
Bretaris Genuair je zdravilo, ki vsebuje zdravilno učinkovino aklidinijev bromid.
Bretaris Genuair is a white or almost white powder.
Zdravilo Bretaris Genuair je bel ali skoraj bel prašek.
Bretaris Genuair is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).
Zdravilo Bretaris Genuair je indicirano za vzdrževalno bronhodilatacijsko zdravljenje za lajšanje simptomov pri odraslih bolnikih s kronično obstruktivno pljučno boleznijo (KOPB).
Bretaris Genuair is indicated for maintenance treatment of your chronic obstructive pulmonary disease, it should not be used to treat a sudden attack of breathlessness or wheezing.
Zdravilo Bretaris Genuair je indicirano za vzdrževalno zdravljenje kronične obstruktivne pljučne bolezni in ga ne smete uporabljati za zdravljenje nenadnega napada zadihanosti ali sopenja.
Bretaris Genuair is indicated to help open the airways and relieve symptoms of COPD, a serious, long-term lung disease characterised by breathing difficulties.
Zdravilo Bretaris Genuair je indicirano za pomoč pri odpiranju dihalnih poti in lajšanju simptomov KOPB, resni, dolgotrajni pljučni bolezni, za katero so značilne dihalne težave.
Bretaris Genuair is not for use in children or adolescents below 18 years of age.
Zdravilo Bretaris Genuair ni namenjeno za otroke ali mladostnike do 18. leta starosti.
Bretaris Genuair is used for maintenance (regular) treatment.
Zdravilo Bretaris Genuair se uporablja za vzdrževalno (redno) zdravljenje.
Bretaris Genuair is used to relieve the symptoms of chronic obstructive pulmonary disease (COPD) in adults.
Zdravilo Bretaris Genuair se uporablja za lajšanje simptomov pri odraslih bolnikih s kronično obstruktivno pljučno boleznijo (KOPB).
Bretaris Genuair may have minor influence on the ability to drive and use machines.
Zdravilo Bretaris Genuair lahko ima blag vpliv na sposobnost vožnje in upravljanja s stroji.
Bretaris Genuair must not be used in people who are hypersensitive (allergic) to aclidinium bromide, atropine, other related anticholinergic bronchodilator medicines, or any of the other ingredients.
Zdravila Bretaris Genuair ne smejo uporabljati osebe, ki so preobčutljive za (alergične na) aklidinijev bromid, atropin, druge povezane antiholinergične bronhodilatatorje ali katero koli drugo sestavino zdravila.
Bretaris Genuair provided clinically meaningful improvements in breathlessness (assessed using the Transition Dyspnoea Index [TDI]) and disease-specific health status (assessed using the St. George’s Respiratory Questionnaire [SGRQ]).
Zdravilo Bretaris Genuair je povzročilo klinično pomembno izboljšanje zadihanosti (ocenjeno s pomočjo indeksa ocene dispneje skozi čas [TDI – Transition Dyspnoea Index]) in od bolezni odvisnega zdravstvenega stanja (ocenjeno s pomočjo dihalnega vprašalnika ustanove St.
Bretaris Genuair should be used with caution in patients with a myocardial infarction during the previous 6 months, unstable angina, newly diagnosed arrhythmia within the previous 3 months, or hospitalisation within the previous 12 months for heart failure functional classes III and IV as per the “New York Heart Association”.
Zdravilo Bretaris Genuair morate pri bolnikih, ki so imeli v zadnjih 6 mesecih miokardialni infarkt, nestabilno angino pektoris, na novo diagnosticirano aritmijo v zadnjih 3 mesecih ali so bili v zadnjih 12 mesecih hospitalizirani zaradi odpovedi srca funkcijskega razreda III in IV po razvrstitvi NYHA (New York Heart Association), uporabljati previdno.
Bretaris Genuair should not be used in asthma; clinical trials of aclidinium bromide in asthma have not been conducted.
Zdravilo Bretaris Genuair ni namenjeno uporabi pri astmi; klinični preizkusi aklidinijevega bromida niso bili izvedeni pri astmi.
Bretaris Genuair was more effective than placebo at improving how well the lungs work in patients with COPD.
Zdravilo Bretaris Genuair je bilo pri izboljšanju delovanja pljuč bolnikov s KOPB učinkovitejše od placeba.
BRF113710 (BREAK-2) was a multicentre, single-arm study that enrolled 92 subjects with metastatic melanoma (Stage IV) with confirmed BRAF V600E or V600K mutation-positive melanoma.
Študija BRF113710 (BREAK-2) je bila multicentrična študija z enim samim krakom, ki je zajela 92 bolnikov z metastatskim melanomom (stadij IV) s potrjeno mutacijo BRAF V600E ali V600K.
Bridging fibrosis
Mostna fibroza
Bridion 100 mg/mL solution for injection sugammadex
Bridion 100 mg/ml raztopina za injiciranje sugamadeks
Bridion can be used during breast-feeding.
Zdravilo Bridion se lahko uporablja med dojenjem.
Bridion can make hormonal contraceptives - including the ‘Pill’, vaginal ring, implants or a hormonal IntraUterine System (IUS) - less effective because it reduces how much you get of the progestogen hormone.
Zdravilo Bridion lahko zmanjša učinkovitost hormonskih kontraceptivov - vključno s "tabletkami", vaginalnim obročkom, implantati (vsadki) ali hormonskimi znotrajmaterničnimi sistemi (IUS), - ker zmanjšuje količino hormona progestogena, ki ga dobite.
Bridion contains sodium
Zdravilo Bridion vsebuje natrij
Bridion has no known influence on your ability to drive and use machines.
Zdravilo Bridion nima znanega vpliva na sposobnost upravljanja vozil in strojev.
Bridion is a clear and colourless to slightly yellow solution for injection.
Bridion je bistra in brezbarvna do rahlo rumena raztopina za injiciranje.
Bridion will be given to you by your anaesthetist, or under the care of your anaesthetist.
Zdravilo Bridion vam bo dal anestezist ali ga boste prejeli pod nadzorom anestezista.
Bridion will be given to you by your anaesthetist.
Zdravilo Bridion vam bo dal anestezist.
Brief background and introduction to Barrett’s oesophagus and high grade dysplasia
Kratek opis in razlaga Barretovega požiralnika ter visoke stopnje displazije
Brief background on lenalidomide and its licensed indication
povzetek podatkov o lenalidomidu in indikacijah, za katere je odobren;
Brief background on pomalidomide and its licensed indication
povzetek podatkov o pomalidomidu in indikaciji, za katero je odobren;
Brief contact of the animal with water on one or two occasions between monthly treatments is unlikely to significantly reduce the efficacy of the product.
Kratek stik živali z vodo enkrat ali dvakrat v času enomesečnega zdravljenja ne zmanjšuje učinkovitosti zdravila.
Brief contact of the animal with water within the month following application is unlikely to reduce the efficacy of the product.
Kratkotrajen stik živali z vodo enkrat ali dvakrat v mesecu po dajanju zdravila, zelo verjetno ne bo zmanjšal učinkovitosti zdravila.
Brief information on preparation and administration instructions.
Kratke informacije o pripravi in dajanju zdravila.
Brief introduction of aripiprazole indication and the purpose of the tool
Kratka predstavitev indikacije za zdravljenje z aripiprazolom in namena brošure.
Brief introduction to aripiprazole indication and the purpose of the tool
Kratka predstavitev indikacije za zdravljenje z aripiprazolom in namena brošure.
Brief introduction to ipilimumab (indication and the purpose of this tool).
Kratka predstavitev ipilimumaba (indikacije in namen brošure).
Brief introduction to ipilimumab indication and the purpose of this tool.
Kratka predstavitev indikacije za uporabo ipilimumaba in namen brošure.
Brief introduction to RAS and its role in the panitumumab mechanism of action
Kratka predstavitev RAS in njegove vloge pri mehanizmu delovanja panitumumaba.
Brief introduction to the Vectibix indication and the purpose of this tool
Kratka predstavitev indikacij zdravila Vectibix in namen tega gradiva.
Briefly press and release red button.
Na kratko pritisnite in spustite rdeči gumb.
Bright red blood in vomit or stools
Svetlo rdečo kri v izbruhani vsebini ali iztrebkih
BRIGHTER was a 3-arm randomised active-controlled study that compared 0.5 mg ranibizumab given as monotherapy or in combination with adjunctive laser photocoagulation to laser photocoagulation alone.
Študija BRIGHTER je bila randomizirana, aktivno kontrolirana študija s tremi študijskimi skupinami, v kateri so zdravljenje z ranibizumabom 0,5 mg v monoterapiji ali v kombinaciji z dodatno lasersko fotokoagulacijo primerjali z zdravljenjem s samo lasersko fotokoagulacijo.
brightness,
pri gledanju,
Brilique affects cells called ‘platelets’ (also called thrombocytes).
Zdravilo Brilique vpliva na celice, ki jih imenujemo trombociti (ali krvne ploščice).
Brilique contains an active substance called ticagrelor.
Zdravilo Brilique vsebuje zdravilno učinkovino, imenovano ticagrelor.
Brilique does not affect tests of pulmonary function.
Zdravilo Brilique ne vpliva na teste delovanja pljuč.
Brilique is not likely to affect your ability to drive or use machines.
Ni verjetno, da bi zdravilo Brilique vplivalo na sposobnost upravljanja vozil in strojev.
Brilique is not recommended for children and adolescents under 18 years.
Zdravilo Brilique ni priporočljivo za otroke in mladostnike, mlajše od 18 let.
Brilique treatment should be initiated with a single 180 mg loading dose (two tablets of 90 mg) and then continued at 90 mg twice daily.
Zdravljenje z zdravilom Brilique je treba začeti z enim 180-mg polnilnim odmerkom (dve tableti po 90 mg) in ga nadaljevati z 90 mg dvakrat na dan.
Brilique, co-administered with acetylsalicylic acid (ASA), is indicated for the prevention of atherothrombotic events in adult patients with acute coronary syndromes (ACS) or a history of myocardial infarction (MI) and a high risk of developing an atherothrombotic event (see sections 4.2 and 5.1).
Zdravilo Brilique je sočasno z acetilsalicilno kislino (ASA) indicirano za preprečevanje aterotrombotičnih dogodkov pri odraslih bolnikih z akutnimi koronarnimi sindromi (AKS) ali anamnezo miokardnega infarkta in velikim tveganjem za pojav aterotrombotičnega dogodka (glejte poglavji 4.2 in 5.1).
Brilliant Blue (E133) Allura Red AC (E129) Titanium dioxide (E171) Sunset Yellow FCF (E110)
želatina briljantno modro (E133) alurno rdeče AC (E129) titanov dioksid (E171) sončno rumeno FCF (E110)
Brimica Genuair 340/12 mcg inhalation powder Aclidinium/Formoterol fumarate dihydrate
Brimica Genuair 340/12 µg prašek za inhaliranje aklidinij/formoterolijev fumarat dihidrat
Brimica Genuair 340/12 micrograms inhalation powder Aclidinium/Formoterol fumarate dihydrate
Brimica Genuair 340/12 mikrogramov prašek za inhaliranje aklidinij/formoterolijev fumarat dihidrat
Brimica Genuair Brimica Genuair Brimica Genuair
Brimica Genuair 340
Brimica Genuair improved daily symptoms of COPD such as ‘breathlessness’, ‘chest symptoms’, ‘cough and sputum’ (assessed by E-RS total score) as well as overall night-time symptoms, overall early morning symptoms and symptoms limiting early morning activities compared to placebo, aclidinium and formoterol but the improvements were not always statistically significant.
Zdravilo Brimica Genuair je v primerjavi s placebom, aklidinijem in formoterolom (vsi p < 0,05) izboljšalo tudi dnevne simptome KOPB, kot so »zasoplost«, »simptomi v prsnem košu«, »kašelj in sputum«, (ocenjene na osnovi celokupne ocene E-RS) ter nočne in zgodnje jutranje simptome ter simptome, ki bolnika omejujejo pri zgodnjih jutranjih aktivnostih, vendar izboljšanja niso bila vedno statistično značilna.
Brimica Genuair is a white or almost white powder.
Zdravilo Brimica Genuair je bel ali skoraj bel prašek.
Brimica Genuair is not for use in children or adolescents below 18 years of age.
Zdravilo Brimica Genuair ni namenjeno za otroke ali mladostnike do 18. leta starosti.
Brimica Genuair is unlikely to affect your ability to drive or use machines.
Malo verjetno je, da bi zdravilo Brimica Genuair vplivalo na vašo sposobnost upravljanja vozil in strojev.
Brimica Genuair provided a clinically meaningful improvement in breathlessness (assessed by the Transition Dyspnoea Index [TDI]) with an improvement in the TDI focal score at 6 months compared to placebo of 1.29 units in study ACLIFORM-COPD (p<0.0001) and 1.44 units in study AUGMENT (p<0.0001).
Zdravilo Brimica Genuair je v primerjavi s placebom klinično pomembno izboljšalo zadihanost (ocenjeno s pomočjo indeksa ocene dispneje skozi čas [TDI – Transition Dyspnoea Index]) z izboljšanjem skupne ocene TDI po 6 mesecih z rezultatom 1,29 enote v študiji ACLIFORM-COPD (p<0,0001) in 1,44 enote v študiji AUGMENT (p<0,001).
Brimonidine did not present any special reproductive or developmental hazard in animal species.
Brimonidin ni predstavljal nobenih posebnih tveganj za razmnoževanje ali razvoj pri živalskih vrstah.
Brimonidine is extensively metabolised by the liver.
Brimonidin se obširno presnavlja v jetrih.
Brimonidine is extensively metabolized by hepatic aldehyde oxidase with formation of 2-oxobrimonidine, 3- oxobrimonidine and 2,3-dioxobrimonidine being the major metabolites.
Brimonidin se obsežno presnovi z jetrno aldehidno oksidazo s tvorbo 2-oksobrimonidina, 3- oksobrimonidina in 2,3-dioksobrimonidina kot glavnih presnovkov.
BRINAVESS cannot be recommended in patients previously administered intravenous AADs (class I and III) 4-24 hours prior to vernakalant due to lack of data.
Zdravila BRINAVESS zaradi pomanjkanja podatkov ne moremo priporočiti bolnikom, ki so 4–24 ur pred vernakalantom prejeli intravenske antiaritmike (skupine I in III).
BRINAVESS cannot be recommended in patients previously administered intravenous AADs (class I and III) 4-24 hours prior to vernakalant, due to lack of data.
Zdravila BRINAVESS zaradi pomanjkanja podatkov ne moremo priporočiti bolnikom, ki so 4–24 ur pred vernakalantom prejeli intravenske antiaritmike (skupine I in III).
BRINAVESS cannot be recommended in patients previously administered intravenous AADs (class I and III) 4-24 hours prior to vernakalant, due to lack of data.
Zdravila BRINAVESS zaradi pomanjkanja podatkov ne moremo priporočiti bolnikom, ki so 4–24 ur pred vernakalantom prejeli intravenski antiaritmik (skupine I in III).
BRINAVESS contains the active substance vernakalant hydrochloride.
Zdravilo BRINAVESS vsebuje zdravilno učinkovino vernakalantijev klorid.
BRINAVESS has a minor to moderate influence on the ability to drive and use machines.
Zdravilo BRINAVESS ima blag do zmeren vpliv na sposobnost vožnje in upravljanje s stroji.
BRINAVESS has been administered to patients with an uncorrected QT less than 440 msec without an increased risk of torsade de pointes.
Zdravilo BRINAVESS so dajali bolnikom z nekorigiranim QT manj kot 440 ms brez večjega tveganja za pojav torsade de pointes.
Brinavess is a concentrate that is made up into a solution for infusion (drip into a vein).
Zdravilo Brinavess je koncentrat za pripravo raztopine za infundiranje (kapalne infuzije v veno).
BRINAVESS is dosed by patient body weight, with a maximum calculated dose based upon 113 kg.
Zdravilo BRINAVESS se odmerja glede na bolnikovo telesno maso z največjim izračunanim odmerkom na podlagi mase 113 kg.
Brinavess is to be used for fibrillation that has started within the last seven days, or within the last three days if the patient had recently had heart surgery.
Zdravilo Brinavess naj bi se uporabljalo pri fibrilaciji, ki se je začela v zadnjih sedmih dneh ali v zadnjih treh dneh, če je bil bolnik nedavno operiran na srcu.
Brinavess is used to rapidly restore normal heart rhythm in adult patients (aged 18 years or over) who have recently started having atrial fibrillation.
Zdravilo Brinavess se uporablja za hitro obnovitev normalnega srčnega utripa pri odraslih bolnikih (starih 18 let ali več) z nedavno nastalo atrijsko fibrilacijo.
BRINAVESS must not be administered in patients who received intravenous AADs (class I and III) within 4 hours prior to vernakalant (see section 4.3).
Zdravila BRINAVESS se ne sme aplicirati bolnikom, ki so v 4 urah pred vernakalantom prejeli intravenske antiaritmike (skupine I in III) (glejte poglavje 4.3).
BRINAVESS must NOT be given to any patients with a “YES” response below:
Zdravila BRINAVESS NE smete dati nobenemu bolniku, pri katerem je vsaj en odgovor pritrdilen:
BRINAVESS should be used with caution in patients on oral AADs (class I and III), due to limited experience.
Zdravilo BRINAVESS je treba pri bolnikih, ki prejemajo peroralne antiaritmike (skupine I in III), zaradi pomanjkanja izkušenj uporabljati previdno.
Brinavess should not be used in people who may be hypersensitive (allergic) to vernakalant hydrochloride or any of the other ingredients.
Zdravila Brinavess ne smejo uporabljati osebe, ki utegnejo biti preobčutljive za (alergične na) vernakalantijev klorid ali katero koli drugo sestavino zdravila.
Brinavess vernakalant hydrochloride
Brinavess vernakalantijev klorid
BRINAVESS was not found to be effective in converting typical primary atrial flutter to sinus rhythm.
Za zdravilo BRINAVESS ni ugotovljeno, da bi učinkovito doseglo prehod tipične primarne atrijske undulacije v sinusni ritem.
BRINAVESS was shown to provide relief of atrial fibrillation symptoms consistent with conversion to sinus rhythm.
Ugotovljeno je bilo, da zdravilo BRINAVESS olajša simptome atrijske fibrilacije, skladno s prehodom v sinusni ritem.
BRINAVESS will be diluted before being given to you.
Pred tem bo zdravilo BRINAVESS razredčil.
Bring it out half an hour before injecting.
Pol ure pred uporabo jo vzemite iz hladilnika.
Bring NovoRapid PumpCart to room temperature.
Zdravilo NovoRapid PumpCart ogrejte na sobno temperaturo.
Bring the bottle tip close to the eye.
Kapalko plastenke približajte očesu.
Bring the bottle tip close to the eye.
Vrh kapalnega vsebnika približajte k očesu.
Bring the bottle tip close to the eye.
Vrh kapalnega vsebnika približajte očesu.
Bring the container tip close to the eye.
Vrh vsebnika približajte očesu.
Bring the OBIZUR powdervial and the pre-filled solvent syringe to room temperature.
Vialo s praškom zdravila OBIZUR in napolnjeno injekcijsko brizgo z vehiklom ogrejte na sobno temperaturo.
Bring the vial and the pre-filled syringe to room temperature (not above 37°C).
Vialo in napolnjeno injekcijsko brizgo ogrejte na sobno temperaturo (do 37 °C).
Bring the vial and the prefilled syringe to room temperature.
Ogrejte vialo in napolnjeno injekcijsko brizgo na sobno temperaturo.
Bring the vial and the prefilled syringe to room temperature.
Vialo in napolnjeno injekcijsko brizgo ogrejte na sobno temperaturo.
Brintellix 20 mg/ml oral drops, solution
Brintellix 20 mg/ml peroralne kapljice, raztopina
Brintellix Brintellix
EU/1/13/891/023
Brintellix film-coated tablets 10 mg are available in blister packs of 7, 14, 28, 56, 56 x 1, 98, 98 x 1,
Zdravilo Brintellix filmsko obložene tablete 10 mg so na voljo v pretisnih omotih s 7, 14, 28, 56, 56 x 1, 98,
Brintellix has been shown to reduce the broad range of depressive symptoms, including sadness, inner tension (feeling anxious), sleep, disturbances (reduced sleep), reduced appetite, difficulty in concentrating, feelings of worthlessness, loss of interest in favourite activities, feeling of being slowed down.
Ugotovljeno je, da zdravilo Brintellix zmanjša širok spekter simptomov depresije, ki zajemajo žalost, notranjo napetost (občutek tesnobe), motnje spanja (zmanjšanje spanja), zmanjšanje apetita, težavo s koncentracijo, občutke ničvrednosti, izgubo zanimanja za stvari, ki so bolnika prej veselile, in občutek splošne upočasnjenosti.
Brintellix oral drops, solution, are available in 20 ml amber glass bottles.
Zdravilo Brintellix peroralne kapljice, raztopina je na voljo v 20 ml steklenicah iz jantarjevega stekla.
Brintellix should not be used during pregnancy unless the clinical condition of the woman requires treatment with vortioxetine.
Zdravila Brintellix ne smete uporabljati pri nosečnicah, razen če klinično stanje nosečnice zahteva zdravljenje z vortioksetinom.
Brintellix should not be used during pregnancy unless thedoctor says it is absolutely necessary.
Zdravila Brintellix ne smete uporabljati med nosečnostjo, razen če zdravnik pravi, da je to nujno potrebno.
Brinzolamide + Brimonidine Meana
Brinzolamid + brimonidin srednja vrednosta
Brinzolamide and
Brinzolamid in
Brinzolamide and N-desethyl-brinzolamide are the predominant components found in the urine along with trace levels (<1%) of the N-desmethoxypropyl and O-desmethyl metabolites.
Tako v seču najdemo predvsem brinzolamid in N-desetil-brinzolamid poleg N-desmetoksipropilnih in O-desmetilnih presnovkov, ki pa so prisotni le v sledovih (<1%).
Brinzolamide and timolol are absorbed systemically.
Brinzolamid in timolol se absorbirata sistemsko.
Brinzolamide belongs to a group of medicines called ‘carbonic anhydrase inhibitors’ and brimonidine tartrate belongs to a group of medicines called ‘alpha-2 adrenergic receptor agonists’.
Brinzolamid sodi v skupino zdravil, ki jim pravimo ‘zaviralci karboanhidraze’, brimonidinijev tartrat pa sodi v skupino zdravil, ki jim pravimo ‘agonisti adrenergičnih receptorjev alfa-2’.
Brinzolamide is a potent inhibitor of human carbonic anhydrase II (CA-II), the predominant iso- enzyme in the eye.
Brinzolamid je močan zaviralec človeškega encima karboanhidraze II (CA-II), prevladujočega izoencima v očesu.
Brinzolamide is absorbed through the cornea following topical ocular administration.
Po topikalni okularni uporabi zdravila se brinzolamid absorbira skozi roženico.
Brinzolamide is eliminated primarily by renal excretion (approximately 60%).
Brinzolamid se izloča predvsem preko ledvic (približno 60%).
Brinzolamide is metabolized by hepatic cytochrome P450 isozymes, specifically CYP3A4, CYP2A6, CYP2B6, CYP2C8 and CYP2C9.
Brinzolamid se presnavlja z izoencimi jetrnega citokroma P450, to so CYP3A4, CYP2A6, CYP2B6, CYP2C8 in CYP2C9.